Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell W Jenkins

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Melanoma Management|September 8, 2018
<i>NRAS</i> mutant melanoma: an overview for the clinician for melanoma managementRussell W Jenkins, Ryan J Sullivan
Cancer Discovery|August 3, 2017
Refining Targeted Therapy Opportunities for <i>BRAF</i>-Mutant MelanomaRussell W Jenkins, David A Barbie
The British Journal of Dermatology|November 15, 2024
Real-world data confirms limited efficacy of dual programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 immune checkpoint blockade in acral lentiginous melanomaDavid X Zheng, Russell W Jenkins
The Journal of Investigative Dermatology|April 9, 2020
Treatment of Advanced Melanoma in 2020 and BeyondRussell W Jenkins, David E Fisher
The American Journal of the Medical Sciences|June 29, 2012
Numb chin syndrome in acute myeloid leukemiaRussell W Jenkins, Kristine McDonald, Charles S Greenberg
Cancers|December 10, 2021
Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic TechnologyHongyan Xie, Jackson W Appelt, Russell W Jenkins
Cellular Signalling|April 23, 2009
Roles and regulation of secretory and lysosomal acid sphingomyelinaseRussell W Jenkins, Daniel Canals, Yusuf A Hannun
American Journal of Clinical Dermatology|September 28, 2018
Mechanisms of Resistance to Immune Checkpoint BlockadeDavid Liu, Russell W Jenkins, Ryan J Sullivan
Expert Opinion on Therapeutic Targets|September 23, 2020
Targeting TANK-binding kinase 1 (TBK1) in cancerOr-Yam Revach, Shuming Liu, Russell W Jenkins
Trends in Cancer|March 22, 2024
Emerging roles of TBK1 in cancer immunobiologyAlex Miranda, Carl A Shirley, Russell W Jenkins
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Melanoma Management|September 8, 2018
<i>NRAS</i> mutant melanoma: an overview for the clinician for melanoma managementRussell W Jenkins, Ryan J Sullivan
Cancer Discovery|August 3, 2017
Refining Targeted Therapy Opportunities for <i>BRAF</i>-Mutant MelanomaRussell W Jenkins, David A Barbie
The British Journal of Dermatology|November 15, 2024
Real-world data confirms limited efficacy of dual programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 immune checkpoint blockade in acral lentiginous melanomaDavid X Zheng, Russell W Jenkins
The Journal of Investigative Dermatology|April 9, 2020
Treatment of Advanced Melanoma in 2020 and BeyondRussell W Jenkins, David E Fisher
The American Journal of the Medical Sciences|June 29, 2012
Numb chin syndrome in acute myeloid leukemiaRussell W Jenkins, Kristine McDonald, Charles S Greenberg
Cancers|December 10, 2021
Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic TechnologyHongyan Xie, Jackson W Appelt, Russell W Jenkins
Cellular Signalling|April 23, 2009
Roles and regulation of secretory and lysosomal acid sphingomyelinaseRussell W Jenkins, Daniel Canals, Yusuf A Hannun
American Journal of Clinical Dermatology|September 28, 2018
Mechanisms of Resistance to Immune Checkpoint BlockadeDavid Liu, Russell W Jenkins, Ryan J Sullivan
Expert Opinion on Therapeutic Targets|September 23, 2020
Targeting TANK-binding kinase 1 (TBK1) in cancerOr-Yam Revach, Shuming Liu, Russell W Jenkins
Trends in Cancer|March 22, 2024
Emerging roles of TBK1 in cancer immunobiologyAlex Miranda, Carl A Shirley, Russell W Jenkins
Pageof 8